BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Risitano AM. Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America 2015;29:561-82. [DOI: 10.1016/j.hoc.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Wen Q, Jin X, Lu Y, Chen D. Anticomplement ent-labdane diterpenoids from the aerial parts of Andrographis paniculata. Fitoterapia 2020;142:104528. [DOI: 10.1016/j.fitote.2020.104528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Risitano AM. Therapeutic complement modulation for hematological diseases: Where we stand and where we are going. Semin Hematol 2018;55:113-7. [PMID: 30032746 DOI: 10.1053/j.seminhematol.2018.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Goncalves MV, Melo LH, Benedet CM, Ribas FD, Cabral NL, Fragoso YD. Eculizumab, Neuromyelitis Optica, and Tuberculosis: We Live An Era of Challenging Combinations. CNS Neurosci Ther 2015;21:914-5. [PMID: 26404521 DOI: 10.1111/cns.12465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Discipio RG, Schraufstatter IU. Magnetic bead based assays for complement component C5. Journal of Immunological Methods 2017;450:50-7. [DOI: 10.1016/j.jim.2017.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Hiemstra PS. Parallel activities and interactions between antimicrobial peptides and complement in host defense at the airway epithelial surface. Molecular Immunology 2015;68:28-30. [DOI: 10.1016/j.molimm.2015.07.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
6 Fattahi F, Ward PA. Anti-inflammatory interventions-what has worked, not worked, and what may work in the future. Transl Res 2016;167:1-6. [PMID: 26323016 DOI: 10.1016/j.trsl.2015.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Leicht HB, Weinig E, Mayer B, Viebahn J, Geier A, Rau M. Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature. BMC Pharmacol Toxicol 2018;19:67. [PMID: 30359322 DOI: 10.1186/s40360-018-0257-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
8 Hajishengallis G, Hajishengallis E, Kajikawa T, Wang B, Yancopoulou D, Ricklin D, Lambris JD. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin Immunol 2016;28:285-91. [PMID: 27021500 DOI: 10.1016/j.smim.2016.03.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
9 Antwi-Baffour S, Kyeremeh R, Adjei JK, Aryeh C, Kpentey G. The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights 2016;7:6. [PMID: 26935316 DOI: 10.1007/s13317-016-0078-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol 2018;181:320-30. [DOI: 10.1111/bjh.15109] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
11 Sepah YJ, Velez G, Tang PH, Yang J, Chemudupati T, Li AS, Nguyen QD, Bassuk AG, Mahajan VB. Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target. Am J Ophthalmol Case Rep 2020;18:100646. [PMID: 32274442 DOI: 10.1016/j.ajoc.2020.100646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Taylor RP, Lindorfer MA. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Semin Immunol 2016;28:309-16. [PMID: 27009480 DOI: 10.1016/j.smim.2016.03.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
13 Yin X, Lu Y, Cheng ZH, Chen DF. Anti-Complementary Components of Helicteres angustifolia. Molecules 2016;21:E1506. [PMID: 27834928 DOI: 10.3390/molecules21111506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Berentsen S. Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease. Semin Hematol 2018;55:141-9. [PMID: 30032751 DOI: 10.1053/j.seminhematol.2018.04.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
15 Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program 2016;2016:226-31. [PMID: 27913484 DOI: 10.1182/asheducation-2016.1.226] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
16 Berentsen S, Röth A, Randen U, Jilma B, Tjønnfjord GE. Cold agglutinin disease: current challenges and future prospects. J Blood Med 2019;10:93-103. [PMID: 31114413 DOI: 10.2147/JBM.S177621] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
17 Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol 2019;10:1157. [PMID: 31258525 DOI: 10.3389/fimmu.2019.01157] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
18 Risitano AM. Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition. Am J Hematol 2016;91:359-60. [DOI: 10.1002/ajh.24323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
19 Kuhn N, Schmidt CQ, Schlapschy M, Skerra A. PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro. Bioconjug Chem 2016;27:2359-71. [PMID: 27598771 DOI: 10.1021/acs.bioconjchem.6b00369] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
20 Berglund MM, Strömberg P. The clinical potential of Affibody-based inhibitors of C5 for therapeutic complement disruption. Expert Review of Proteomics 2016;13:241-3. [DOI: 10.1586/14789450.2016.1148604] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
21 Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Mol Oral Microbiol 2016;31:3-17. [PMID: 26332138 DOI: 10.1111/omi.12129] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
22 Gaggl M, Aigner C, Sunder-Plassmann G, Schmidt A. [Thrombotic microangiopathy : Relevant new aspects for intensive care physicians]. Med Klin Intensivmed Notfmed 2016;111:434-9. [PMID: 27255224 DOI: 10.1007/s00063-016-0176-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Gabizon A, Szebeni J. Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines. ACS Nano 2020;14:7682-8. [PMID: 32643376 DOI: 10.1021/acsnano.0c03648] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
24 Khameneh HJ, Ho AW, Laudisi F, Derks H, Kandasamy M, Sivasankar B, Teng GG, Mortellaro A. C5a Regulates IL-1β Production and Leukocyte Recruitment in a Murine Model of Monosodium Urate Crystal-Induced Peritonitis. Front Pharmacol 2017;8:10. [PMID: 28167912 DOI: 10.3389/fphar.2017.00010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
25 Chiorean RM, Baican A, Mustafa MB, Lischka A, Leucuta DC, Feldrihan V, Hertl M, Sitaru C. Complement-Activating Capacity of Autoantibodies Correlates With Disease Activity in Bullous Pemphigoid Patients. Front Immunol 2018;9:2687. [PMID: 30524436 DOI: 10.3389/fimmu.2018.02687] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]